^
Association details:
| Biomarker: | ATM deletion + SF3B1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
Published date:
11/06/2019
Excerpt:
...7 BCR signaling inhibitors (BCRi, including PI3K inhibitors idelalisib, duvelisib, umbralisib...Notably, Sf3b1mut/Atmdel CLL cells were more resistant to the panel of BCRi than MDR cells (p=0.046, the Van Elteren test) and their dependence on BCL-2 for survival after BCRi was likewise diminished (p=0.018, the Van Elteren test…
DOI:
https://doi.org/10.1182/blood-2019-127293
